BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 9658192)

  • 1. Etoposide targets topoisomerase IIalpha and IIbeta in leukemic cells: isoform-specific cleavable complexes visualized and quantified in situ by a novel immunofluorescence technique.
    Willmore E; Frank AJ; Padget K; Tilby MJ; Austin CA
    Mol Pharmacol; 1998 Jul; 54(1):78-85. PubMed ID: 9658192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differences in the longevity of topo IIalpha and topo IIbeta drug-stabilized cleavable complexes and the relationship to drug sensitivity.
    Errington F; Willmore E; Leontiou C; Tilby MJ; Austin CA
    Cancer Chemother Pharmacol; 2004 Feb; 53(2):155-62. PubMed ID: 14504921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced etoposide sensitivity following adenovirus-mediated human topoisomerase IIalpha gene transfer is independent of topoisomerase IIbeta.
    Zhou Z; Zwelling LA; Ganapathi R; Kleinerman ES
    Br J Cancer; 2001 Sep; 85(5):747-51. PubMed ID: 11531262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Camptothecin-stabilised topoisomerase I-DNA complexes in leukaemia cells visualised and quantified in situ by the TARDIS assay (trapped in agarose DNA immunostaining).
    Padget K; Carr R; Pearson AD; Tilby MJ; Austin CA
    Biochem Pharmacol; 2000 Mar; 59(6):629-38. PubMed ID: 10677579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Murine transgenic cells lacking DNA topoisomerase IIbeta are resistant to acridines and mitoxantrone: analysis of cytotoxicity and cleavable complex formation.
    Errington F; Willmore E; Tilby MJ; Li L; Li G; Li W; Baguley BC; Austin CA
    Mol Pharmacol; 1999 Dec; 56(6):1309-16. PubMed ID: 10570059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Formation and longevity of idarubicin-induced DNA topoisomerase II cleavable complexes in K562 human leukaemia cells.
    Willmore E; Errington F; Tilby MJ; Austin CA
    Biochem Pharmacol; 2002 May; 63(10):1807-15. PubMed ID: 12034365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An investigation into the formation of N- [2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA) and 6-[2-(dimethylamino)ethylamino]- 3-hydroxy-7H-indeno[2, 1-C]quinolin-7-one dihydrochloride (TAS-103) stabilised DNA topoisomerase I and II cleavable complexes in human leukaemia cells.
    Padget K; Stewart A; Charlton P; Tilby MJ; Austin CA
    Biochem Pharmacol; 2000 Sep; 60(6):817-21. PubMed ID: 10930536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Altered drug interaction and regulation of topoisomerase IIbeta: potential mechanisms governing sensitivity of HL-60 cells to amsacrine and etoposide.
    Grabowski DR; Holmes KA; Aoyama M; Ye Y; Rybicki LA; Bukowski RM; Ganapathi MK; Hickson ID; Ganapathi R
    Mol Pharmacol; 1999 Dec; 56(6):1340-5. PubMed ID: 10570063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benzene metabolites antagonize etoposide-stabilized cleavable complexes of DNA topoisomerase IIalpha.
    Baker RK; Kurz EU; Pyatt DW; Irons RD; Kroll DJ
    Blood; 2001 Aug; 98(3):830-3. PubMed ID: 11468185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topotecan-induced topoisomerase IIalpha expression increases the sensitivity of the CML cell line K562 to subsequent etoposide plus mitoxantrone treatment.
    Chen S; Gomez SP; McCarley D; Mainwaring MG
    Cancer Chemother Pharmacol; 2002 May; 49(5):347-55. PubMed ID: 11976828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in subcellular distribution of topoisomerase IIalpha correlate with etoposide resistance in multicell spheroids and xenograft tumors.
    Oloumi A; MacPhail SH; Johnston PJ; BanĂ¡th JP; Olive PL
    Cancer Res; 2000 Oct; 60(20):5747-53. PubMed ID: 11059769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of novel human leukemic cell lines selected for resistance to merbarone, a catalytic inhibitor of DNA topoisomerase II.
    Kusumoto H; Rodgers QE; Boege F; Raimondi SC; Beck WT
    Cancer Res; 1996 Jun; 56(11):2573-83. PubMed ID: 8653700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of sensitivity to doxorubicin and etoposide by transfection of MCF-7 breast cancer cells with heregulin beta-2.
    Harris LN; Yang L; Tang C; Yang D; Lupu R
    Clin Cancer Res; 1998 Apr; 4(4):1005-12. PubMed ID: 9563896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA topoisomerase II expression, stability, and phosphorylation in two VM-26-resistant human leukemic CEM sublines.
    Chen M; Beck WT
    Oncol Res; 1995; 7(2):103-11. PubMed ID: 7579726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topotecan increases topoisomerase IIalpha levels and sensitivity to treatment with etoposide in schedule-dependent process.
    Whitacre CM; Zborowska E; Gordon NH; Mackay W; Berger NA
    Cancer Res; 1997 Apr; 57(8):1425-8. PubMed ID: 9108439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transfection of a human topoisomerase II alpha gene into etoposide-resistant human breast tumor cells sensitizes the cells to etoposide.
    Asano T; An T; Zwelling LA; Takano H; Fojo AT; Kleinerman ES
    Oncol Res; 1996; 8(3):101-10. PubMed ID: 8823806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carbamate analogues of amsacrine active against non-cycling cells: relative activity against topoisomerases IIalpha and beta.
    Turnbull RM; Meczes EL; Perenna Rogers M; Lock RB; Sullivan DM; Finlay GJ; Baguley BC; Austin CA
    Cancer Chemother Pharmacol; 1999; 44(4):275-82. PubMed ID: 10447574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of resistance to etoposide and adriamycin in a human glioma cell line treated with antisense oligodeoxynucleotide complementary to the messenger ribonucleic acid of deoxyribonucleic acid topoisomerase II alpha.
    Kuriyama M; Tsutsui K; Tsutsui K; Ono Y; Tamiya T; Matsumoto K; Furuta T; Ohmoto T
    Neurol Med Chir (Tokyo); 1997 Sep; 37(9):655-61; discussion 661-2. PubMed ID: 9330528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of proteasomal degradation in the cell cycle-dependent regulation of DNA topoisomerase IIalpha expression.
    Salmena L; Lam V; McPherson JP; Goldenberg GJ
    Biochem Pharmacol; 2001 Apr; 61(7):795-802. PubMed ID: 11274964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of cell cycle and oncogene activity upon topoisomerase IIalpha expression and drug toxicity.
    Stacey DW; Hitomi M; Chen G
    Mol Cell Biol; 2000 Dec; 20(24):9127-37. PubMed ID: 11094065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.